This study is testing a drug called zanidatamab for people with certain advanced or metastatic solid tumors that have high levels of a protein called HER2 (Human Epidermal Growth Factor Receptor 2). This includes breast, gastric (stomach), esophageal, gastroesophageal, and colorectal cancers. You might be able to join if your cancer has progressed after at least one previous treatment. The main goal is to see how many participants respond to zanidatamab, meaning their tumors shrink or stop growing, over a period of up to 2.5 years. The study is currently unclear about its recruitment status.

Study design

This is a Phase 2 study aiming to enroll 200 participants. It is an interventional study, meaning participants will receive a specific treatment.

What's involved

Zanidatamab is given through an intravenous (IV) infusion. The primary endpoint is measured for up to 2.5 years.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, confirmed Objective Response Rate, is assessed for up to 2.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.